Another Myriad patent challenge on the horizon
This article was originally published in Clinica
Executive Summary
Following news of the challenge last week by organisations in France and Germany to a second patent awarded to Myriad Genetics (US), it transpires that the Myriad patent for diagnosing mutations to the BRCA2 gene in breast and ovarian cancer screening, is due for issue before autumn this year.